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Abstract 
Flavonoids are widely distributed phytochemicals in vegetables, fruits and medicinal 
plants. Recent studies demonstrate that some natural flavonoids are potent inhibitors of the 
human UDP-glucuronosyltransferase 1A1 (UGT1A1), a key enzyme in detoxification of 
endogenous harmful compounds such as bilirubin. In this study, the inhibitory effects of 56 
natural and synthetic flavonoids on UGT1A1 were assayed, while the structure–inhibition 
relationships of flavonoids as UGT1A1 inhibitors were investigated. The results 
demonstrated that the C-3 and C-7 hydroxyl groups on the flavone skeleton would enhance 
UGT1A1 inhibition, while flavonoid glycosides displayed weaker inhibitory effects than their 
corresponding aglycones. Further investigation on inhibition kinetics of two strong 
flavonoid-type UGT1A1 inhibitors, acacetin and kaempferol, yielded interesting results. Both 
flavonoids were competitive inhibitors against UGT1A1-mediated NHPN-O-glucuronidation, 
but were mixed and competitive inhibitors toward UGT1A1-mediated 
NCHN-O-glucuronidation, respectively. Furthermore, docking simulations showed that the 
binding areas of NHPN, kaempferol and acacetin on UGT1A1 were highly overlapping, and 
convergence with the binding area of bilirubin within UGT1A1. In summary, detailed 
structure-inhibition relationships of flavonoids as UGT1A1 inhibitors were investigated 
carefully and the findings shed new light on the interactions between flavonoids and 
UGT1A1, and will contribute considerably to the development of flavonoid-type drugs 
without strong UGT1A1 inhibition. 
Keywords: Flavonoids; UGT1A1; Structure-inhibition relationships  
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1. Introduction 
Flavonoids are polyphenolic phytochemicals that are commonly present in the human diet, 
since they are abundant in vegetables, fruits, and a wide variety of other edible plants 
[1-3]. As an important class of bioactive compounds, flavonoids display many beneficial 
effects on human health, such as antioxidant, anti-inflammatory, anti-proliferative, anti-tumor, 
anti-microbial, and estrogenic-like activities, as well as regulatory effects on various enzymes 
[4-8]. Flavonoids-containing herbs, beverages (such as tea and coffee) or dietary supplements 
are often used for the prevention of various human diseases, such as diabetes, osteoporosis 
and cancer that are caused by free-radical damage, and as adjuvant treatment for liver injury, 
cardiovascular diseases and neurodegenerative disorders [9-12]. The positive effects on 
human health are combined with only very minor side effects that flavonoids have, prompting 
many researchers and biomedical companies to develop health-care foods or flavonoid-type 
drugs for clinical use. At present, some of the flavones from natural origin like silymarin 
(Milk Thistle), gingko flavone glycosides (Gingko Smart), naringenin (Natural Female 
Support), and synthetic flavonoid-type drugs (such as flavopiridol), are commercially 
available in the market. In China, several flavonoids-containing herbs, or flavone mixtures 
(such as baicalin and sliymarin) have been widely used for treatment of hepatitis [13-14]. 
Meanwhile, some natural flavones (such as oroxylin A, wogonin and vitexin) are undergoing 
phase I/II clinical trials in China, for auxiliary treatment of cancer or coronary heart diseases 
[15-17]. 
It is well-accepted that the drug-drug interaction potentials should be carefully investigated 
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during preclinical development process of drug candidates [18-19]. Over the past 
twenty-years, many studies have been conducted to explore the regulatory effects of natural 
and synthetic flavones on drug metabolizing enzymes or transporters [20-22]. The results 
demonstrated that several polyphenolic flavones (such as baicalein and diosmetin) can 
strongly inhibit the activities of some human cytochrome P450 enzymes (CYPs), while other 
polymethoxylated flavones (such as tangeretin and nobiletin) are potent inhibitors of the 
multidrug transporter P-glycoprotein [23-27]. These investigations suggested that flavones 
could reduce the elimination of many therapeutic drugs that are substrates for CYPs or 
P-glycoprotein, thereby causing clinically relevant herb/food-drug interactions (HDIs) [28]. 
The inhibitory effects of natural and synthetic flavones against phase II metabolizing 
enzymes, however, were rarely reported. This is somewhat surprising, considering that many 
flavones are substrates for phase II metabolizing enzymes such as the 
UDP-glucuronosyltransferases (UGTs) [29-30]. As UGTs substrates, flavones could lead to 
undesirable effects via competitive inhibition by occupying the ligand-binding pockets in the 
substrate domain of the UGT enzymes [31].  
Mammalian UDP-glucuronosyltransferases are important endoplasmic reticulum-bound 
enzymes, which catalyze the conjugation of the glucuronic acid moiety from the donor 
UDP-glucuronic acid (UDPGA) to a variety of compounds, thus forming water-soluble 
glucuronides that are more easily eliminated [32-33]. In human, there are over twenty 
different UGTs and the majority of them are expressed in the liver and/or the small intestine 
[33-35]. Among all known human UGTs, UGT1A1 is of particular importance due to its 
crucial role in the metabolic elimination and detoxification of bilirubin, a major product of 
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hemoglobin metabolism, as well as several clinical drugs like cancer chemotherapy drug 
etoposide, the topoisomerase inhibitor SN-38 (the active metabolite of CPT-11), and the 
anti-AIDS agent raltegravir [36-39].  
Impairment or considerable inhibition of UGT1A1 activity may lead to disorders in 
bilirubin metabolism, such as hyperbilirubinemia and jaundice, which may also be triggered 
by significant drug/herb-drug interactions (DDIs or HDIs) [40-42]. Previous studies have 
demonstrated that both therapeutic drugs and natural flavonoid-containing compounds in 
herbs or foods, including indinavir, erlotinib, regorafenib, licochalcone A, bavachin, corylifol 
A, and amentoflavone can strongly inhibit the catalytic activities of UGT1A1, thereby reduce 
bilirubin elimination and trigger clinically relevant drug–drug interactions [43-48]. Thus, it is 
important to systematically assay the inhibitory effects of flavonoids on the human UGT1A1 
and to explore structure-inhibition relationships among them with respect to UGT1A1 
inhibition. Such an investigation will be valuable for developing new flavonoid-type drugs 
with improved safety profiles, and for avoiding or minimizing the occurrence of adverse side 
effects via UGT1A1 inhibition by flavonoids-containing products. 
In the present study, more than fifty flavonoids were collected and their inhibitory effects 
on the human UGT1A1 were investigated carefully. A florescence-based biochemical assay 
was constructed for high-throughput screening of UGT1A1 inhibitors, in which the newly 
developed fluorescent substrate for UGT1A1 was used as a probe [47, 49-50] and human 
liver microsomes (HLM) as the enzyme source. The potential structure-inhibition 
relationships of these structurally diverse flavonoids have been summarized and discussed. In 
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order to deepen our understanding of the interactions between flavonoids and UGT1A1, the 
inhibition kinetics of acacetin and kaempferol, the most potent UGT1A1 inhibitors among all 
tested flavonoids, were carefully examined, using two different probe substrates for UGT1A1. 
Our results strongly support the need to investigate the inhibitory effects of natural flavones 
and their derivatives toward human UGTs, especially those that are responsible for the 
elimination of endogenous toxins or clinical drugs with narrow therapeutic windows [32, 
51-52]. 
 
2. Material and methods 
2.1. Chemicals and reagents  
Pooled human liver microsomes (HLMs, from 50 donors, lot no. X008067) were obtained 
from BioreclamationIVT (Baltimore, MD, USA). Tris-HCl, 7-hydroxycoumarin, 
uridine-5'-diphosphoglucuronic acid (UDPGA) trisodium salt and polyethylene glycol 
hexadecyl ether (Brij 58) were obtained from Sigma-Aldrich (St. Louis, MO, USA). 
N-3-carboxy propyl-4-hydroxy-1,8-naphthalimide (NCHN) and 
N-butyl-4-(4-hydroxyphenyl)-1,8-naphthalimide (NHPN) were chemically synthesized in our 
lab as previously reported [47, 53]. 5,6-dihydroxyflavone, 5,7-dihydroxyflavove, 
6,7-dihydroxyflavove, and 3',4'-dihydroxyflavone were purchased from Alfa Aesar (Ward 
Hill, MA). 3-hydroxyflavone, 5-hydroxyflavone, 6-hydroxyflavone, 6-methoxyflavone and 
7,8-dihydroxyflavone were purchased from TCI (Tokyo, Japan). 
5-hydroxy-6-methoxyflavone, 7-methoxybaicalein, 6,7-dimethoxybaicalein, 
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5,6,7-trimethoxybaicalein and 8-nitrobaicalein were synthesized by the author (Dr. Ping 
Wang), the synthetic details and structural characterization of these compounds were 
described previously [54]. Norwogonin and 8-methoxykaempferol were purchased from 
ChemFaces (Wuhan, China). Isorhamnetin, eupatilin, icaritin, fisetin, and morin were 
purchased from Sichuan Weikeqi Biotechnology Company (Chengdu, Sichuan, China). Other 
flavonoids that were used in this study were purchased from Chengdu Pufei De Biotech Co., 
Ltd. (Chengdu, Sichuan, China). The flavonoids purity was above 98% by LC-UV analysis. 
All other reagents were of HPLC grade or of the highest grade commercially available. 
2.2 Florescence-based enzyme inhibition assay 
2.2.1 NCHN-O-glucuronidation based inhibition assay 
The inhibitory effects of flavonoids on NCHN glucuronidation by the human UGT1A1, 
were investigated in HLM. A typical incubation mixture (total volume of 200 µL), consisted 
of HLM (0.2 mg/mL), 2 mM UDPGA, 5 mM MgCl2, 50 mM Tris-HCl (pH = 7.4), Brij 58 
(0.1 mg/mg protein) and the probe substrate NCHN. The NCHN concentration in the initial 
screening assays was 20 µM and the tested flavonoid concentrations were 1, 10 and 100 µM. 
In experiments for inhibition constant determination, the NCHN concentration was changed 
between 15 and 100 µM, whereas the flavonoids concentrations were between 1 and 80 µM. 
HLM were first pre-incubated with Brij 58 (0.1 mg/mg microsomal protein, make the 
structure of the enzyme flipping to remove the latency) on ice for 20 min and then at 37℃ for 
3 min. The reaction was initiated by adding 10 μL of UDPGA and continued for 40 min (in 
the case of HLM) at 37℃, before termination by the addition of 200 μL acetonitrile. The 
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incubation mixtures were subsequently centrifuged at 20,000 ×g, 4℃ for 20 min and 200 μL 
aliquots of the supernatants were diverted into black 96-well plates for determining the 
fluorescence intensity of NCHN-O-glucuronide, in accordance with our previously published 
methods [43, 55-56]. A positive control (positive inhibitor, PPT) was also carried out under 
the same conditions. NCHN and each flavonoid compound were dissolved in DMSO to a 
final concentration of 1% (v/v).  
2.2.2 NHPN-O-glucuronidation based inhibition assay 
The inhibitory effects of flavonoids on UGT1A1 activity of selected flavonoids, acacetin 
and kaempferol, was also investigated using a second specific fluorescent probe substrate, 
NHPN. The incubation mixture in this case (total volume of 200 µL) contained 0.1 mg/mL 
HLM, 50 mM Tris-HCl (pH = 7.4), Brij 58 (0.1 mg/mg microsomal protein, make the 
structure of the enzyme flipping to remove the latency), 2 mM UDPGA, 5 mM MgCl2, and 
NHPN at varying concentrations from 1 to 40 µM, for inhibition constant determination. The 
inhibitor concentrations (acacetin or kaempferol), in these inhibition constant determination 
analyses were ranged from 1 and 100 µM. All incubations, from preincubation to termination 
and subsequent centrifugation, were carried out as described above for NCHN 
O-glucuronidation, and the fluorescence determination of NHPN concentration was carried 
out as previously described [42, 46-47]. NHPN and each of the flavonoids were dissolved in 
DMSO, at a final concentration of 1% (v/v). 
2.2.3 Inhibition kinetic analyses 
The residual activity of UGT1A1 was calculated as follow: residual activity (%) = (the 
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fluorescence intensity of NCHNG or NHPNG formed in the incubation sample in the 
presence of inhibitor)/(the fluorescence intensity of NCHNG or NHPNG formed in the 
incubation samples in the absence of inhibitor) × 100%. The half maximal inhibition 
concentration (IC50) was determined by using different concentrations of the flavonoids 
compounds with the same fluorescent substrate concentration. The inhibition kinetic modes 
and the corresponding inhibition constant (Ki) values were determined by performing a set of 
analyses in which the concentrations of both the fluorescent substrate and the flavonoid 
compound were changed [57-60]. The following equations for competitive inhibition Eq. (1), 
noncompetitive inhibition Eq. (2), or mixed inhibition Eq. (3) were used to calculate the Ki 
values. 
V=(VmaxS)/ [Km (+I/Ki) +S]                     (1) 
V=(VmaxS)/ [(Km+S) (1+I/Ki)]                    (2) 
V=(VmaxS)/ [(Km+S) (1+I/αKi)]                     (3) 
where V is the velocity of the reaction; Vmax is the maximum velocity; S and I are the 
substrate and inhibitor concentrations, respectively; Km is the Michaelis constant (substrate 
concentration at 0.5 Vmax); Ki is the inhibition constant describing the affinity of the inhibitor 
towards the target enzyme (UGT1A1). 
2.2.4 Molecular docking simulations 
A knowledge-based comparative modelling method (SYBYL Advanced Protein Modeling 
Package) was used to construct a 3D structure of UGT1A1. Using the ORCHESTRAR 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
11 
module in the APM software package, we established a full-atom model of UGT1A1 that is 
based on the amino acid sequence of the enzyme and several known structural homologues. 
The Homo sapiens sequence of UGT1A1 (accession number NP_000454.1) was obtained 
from NCBI. After searching for similarity among target sequences and homologues in the 
protein database using a fugue module, the crystal structure of UDP-glucosyltransferase GtfB 
(PDB code = 1IIR) was selected as the homology template. On the basis of this template, a 
backbone was constructed, as well as structurally-conserved regions (SCR) and models of 
variable regions of the structure. Finally, a three-dimensional model of UGT1A1 was 
obtained through following energy minimization optimization.  
Using the Surflex-Dock software package, the ligand interaction mode and binding affinity 
of the compounds with the constructed UGT1A1 model was studied. Surflex-dock uses a 
patented search engine to link the ligands to the active site of the protein and uses an 
empirical scoring function to evaluate the binding. The established 3D model of UGT1A1 
was prepared as an acceptor by adding missing residues and calculating the partial charge of 
AMBER7FF99. Four compounds, namely NCHN, NHPN, acacetin, and kaempferol, were 
optimized by energy minimization and conformational search using a Tripos field. The gas 
charge was calculated using the Gasteiger-Huckel charge method. The automated mode was 
used to generate the active site in combination with each substrate, and the float radius was 
set to 3. The protein-ligand complexes with the highest LibDock score were taken from the 
docking results and are depicted in full text. 
2.2.5 Data analysis 
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The kinetic and inhibition experiments were performed in triplicate. All values obtained 
from experiments are expressed as mean ± SD. The IC50 and Ki values were obtained by 
nonlinear regression using Graph Pad Prism 6.0 software (Graph Pad Software, Inc., La Jolla, 
CA, USA). Goodness-of-fit parameters were employed to identify the most appropriate 
inhibition mode [61].
  
 
3. Results and discussion 
3.1 Screening flavonoids for inhibition potentials against UGT1A1 
In this study, to systematically explore the structure-inhibition relationships of flavones as 
UGT1A1 inhibitors, we have collected 56 flavones and assayed their inhibitory effects on the 
human UGT1A1, using a fluorescence-based biochemical assay [47]. Firstly, the inhibition 
potentials of all collected flavones against UGT1A1 catalyzing NCHN-O-glucuronidation 
were screened (Figure 1), taking advantage of the high fluorescence intensity and 
UGT1A1-specificity of NCHN as glucuronidation substrate in HLM [47]. The results 
revealed that most of the tested flavones inhibited UGT1A1-mediated 
NCHN-O-glucuronidation by 50% or more at the high concentration (Figure 1). However, 
there were some compounds, such as 2, 4, 16 and 42, that did not have a significant effect. A 
unique exception within the current flavonoids collection was the result with 
6-methoxyflavone, compound no. 10, that clearly activated UGT1A1 by about 2-fold (Figure 
1). 
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After the first inhibition screen, the dose-inhibition curves of the flavonoids for UGT1A1 
were depicted, using different inhibitor concentrations (Figures S2 to S6), and the derived 
IC50 values of all the tested flavonoids were listed in Table 1. In addition to the flavonoids in 
our collection, UGT1A1 inhibition by protopanaxatriol (PPT), a known UGT1A1 inhibitor, 
was used as a positive control [62-63]. Twenty-one flavones displayed strong inhibition of 
UGT1A1, with IC50 values lower than 10 μM (Table 1). Among them, 
6,7-dimethoxybaicalein (11; IC50 value 5.4 μM), 7,4'-dihydroxyflavone (15; 3.6 μM), 
apigenin 7-O-methyl ether (31; 4.8 μM), hispidulin (32; 6.2 μM), acacetin (37; 3.6 μM), 
galangin (45; 5.0 μM), morin (48; 4.2 μM), kaempferol (50; 3.3 μM) and anhydroicaritin (53; 
3.9 μM) were more potent inhibitors of UGT1A1 than the positive control PPT (IC50 = 6.5 
μM). These findings demonstrate that many natural flavonoids can strongly inhibit the 
enzymatic activity of UGT1A1, suggesting that medicinal plants that are rich in flavonoids 
might trigger metabolic disorder of bilirubin metabolism via UGT1A1 inhibition.   
3.2 Structure-inhibition relationships of flavonoids against UGT1A1  
It appears from the results in Table 1 that the inhibitory effects of flavonoids on UGT1A1 
may depend on the number and position of phenolic hydroxyl groups in the flavonoid 
skeleton. The structure-inhibition relationships of flavonoids with respect to the human 
UGT1A1 catalyzing NCHN-O-glucuronidation, as derived from our experimental results, are 
summarized in Figure 2. It is suggested that a hydroxyl group at the C-3 site will enhance 
UGT1A1 inhibition, as indicated by the following pairs (or small group): 
5,7-dihydroxyflavone 7 (9.40 μM) vs. galangin 45 (5.03 μM), apigenin 29 (18.57 μM) vs. 
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kaempferol 50 (3.34 μM), as well as luteolin 24 (7.78 μM) and quercetin 46 (7.47 μM). 
Another observation was that a hydroxyl group at the C-5 site in the A ring, forming either a 
catechol or a pyrogallol group, enhances the inhibitory effects on UGT1A1, as demonstrated 
by 6,7-dihydroxyflavone 12 (23.20 μM) vs. baicalein 18 (12.43 μM) and 6-hydroxyflavone 9 
(17.29 μM) vs. 5,6-dihydroxyflavone 5 (16.29 μM). However, 5-OH that forms a resorcinol 
structure may decrease the inhibition activity, as shown by comparing 7,8-dihydroxyflavone 
14 (30.89 μM) and norwogonin 35 (51.32 μM), as well as 7,4'-dihydroxyflavone 15 (3.65 μM) 
and apigenin 29 (18.57 μM). These findings suggested that, if not forming a resorcinol group, 
a catechol or pyrogallol group at the 5-OH position on the flavonoid skeleton could stimulate 
UGT1A1 inhibition. 
Remarkably, the hydroxyl group at the C-8 site had a significantly negative impact on 
UGT1A1 inhibition, but inhibition was recovered when the 8-hydroxyl group was replaced 
by a methoxy group, such as in 5,7-dihydroxyflavone 7 (9.40 μM) and wogonin 22 (10.01 
μM) vs. norwogonin 35 (51.32 μM), as well as kaempferol 50 (3.34 μM) and 
8-methoxykaempferol 51 (6.56 μM) vs. herbacetin 49 (56.13 μM). These results suggested 
that introducing a hydrophilic group at the flavones’ C-8 site would decrease UGT1A1 
inhibition. To test this assumption, compound 41 and 42 were semi-synthesized by 
introducing a hydrophilic tertiary amine group at the C-8 site of baicalein and 
7-hydroxyflavone, respectively. The results showed that the IC50 values of compound 41 and 
42 were 69.20 μM and more than 100 μM, respectively. These findings strongly support 
introduction of a hydrophilic group at the C-8 of flavones as a way to reduce its inhibitory 
effect on UGT1A1. Meanwhile, such structural modification would also improve the 
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metabolic stability of these flavones, enhance their water solubility and could potentially 
reduce liver toxicity [64-65]. It should also be added that flavonoid glycosides displayed very 
weakly inhibition on UGT1A1-mediated NCHN-O-glucuronidation, in comparison to the 
corresponding aglycones. These experimental data may be regarded as a proof of concept that 
to improve the metabolic stability and the safety profiles of some investigational new drugs 
(especially for flavonoid-type drug candidates) without strong UGT1A1 inhibition. 
3.3 Inhibition mechanism 
Considering that the wide distribution of acacetin and kaempferol in herbs or vegetables, as 
well as their strong inhibition of the human UGT1A1, we further investigated the inhibition 
mechanism of these two flavonoids toward UGT1A1. In this part, two highly specific 
florescent probes for UGT1A1, NCHN and NHPN, were used to explore the interactions of 
these two UGT1A1 inhibitors with the ligand-binding sites of UGT1A1, as well as to 
investigate their inhibition kinetics. Notably, a recent study has demonstrated that NCHN and 
NHPN may bind at different ligand-binding sites within UGT1A1, only one of them, the 
NHPN site, also binds bilirubin [47]. Thus, NCHN and NHPN could be used as site-specific 
makers for UGT1A1 ligands, at least for the two important ligand-binding sites we are 
currently certain about [47]. 
3.3.1 UGT1A1 Inhibition by acacetin 
In HLM, acacetin could inhibit UGT1A1-mediated both NCHN-O-glucuronidation and 
NHPN-O-glucuronidation activity at almost identical IC50 values of 3.57 µM, and 3.84 µM, 
respectively (Figure 3A & 3B). Further inhibition assays in HLM were carried out and the 
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results demonstrated that the inhibition of both NCHN- and NHPN-O-glucuronidation by 
acacetin was not time-dependent (Figure S7), suggesting that acacetin was a reversible 
inhibitor of this enzyme. Lineweaver-Burk plots demonstrated that acacetin functioned as a 
mixed inhibitor of NCHN-O-glucuronidation in HLM (Figure 3C), while competitive 
inhibitor of the NHPN-O-glucuronidation in HLM (Figure 3D). The Ki values of acacetin, in 
HLM, for NCHN-O-glucuronidation and NHPN-O-glucuronidation were 8.56±0.87 µM and 
5.95±0.16 µM, respectively. However, careful analysis of the NCHN-O-glucuronidation 
inhibition kinetics by acacetin indicated that it is of a mixed type and the value of the second, 
only little higher αKi value is 32.57±1.43 µM. This explains why the inhibition of HLM 
catalyzed NCHN glucuronidation by acacetin appeared first nearly as competitive. 
3.3.2 UGT1A1 Inhibition by kaempferol  
UGT1A1 inhibition by kaempferol was investigated in a similar way to the assays with 
acacetin, using both NCHN and NHPN as UGT1A1 probe substrates. Hence the inhibition 
kinetic mode was determined for each of the two reactions, and the corresponding Ki values 
of kaempferol for them were calculated. As shown in Figure 4, kaempferol efficiently 
inhibited both NCHN-O-glucuronidation and NHPN-O-glucuronidation in HLM, exhibiting 
IC50 values of 3.34 µM, and 2.33 µM, respectively (Figure 4A & 4B). Time-dependent 
inhibition assays demonstrated that in both cases the inhibition was not time-dependent 
(Figure S7), suggesting that kaempferol is also a reversible inhibitor of UGT1A1. 
Lineweaver-Burk plots revealed that kaempferol functions as a noncompetitive inhibitor 
toward NCHN-O-glucuronidation in HLM (Figure 4C). Unlike NCHN-O-glucuronidation, 
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the inhibition of NHPN-O-glucuronidation in HLM by kaempferol was clearly competitive 
(Figure 4D). The Ki values of kaempferol were 1.74±0.29 µM and 0.68±0.24 µM for the 
inhibition of NCHN- and NHPN- O-glucuronidation reactions, respectively. These findings 
indicate that kaempferol is a particularly strong inhibitor of the human UGT1A1. Moreover, 
this compound binds at the NHPN binding site, also named the bilirubin-binding site. Hence, 
our findings suggest that uptake of kaempferol into the liver, so that its concentration will 
approach 0.4-0.5 µM, could start interfering with bilirubin conjugation, perhaps even leading 
to hyperbilirubinemia in some individuals, particularly those that have low expression level 
of the enzyme, as in the rather common Gilbert’s Syndrome. Acacetin is a strong inhibitor of 
UGT1A1 as well, even if not as strong as kaempferol. It might be added that when 
considering the possible risks of these and other flavonoids for bilirubin glucuronidation by 
UGT1A1, one also has to consider the rates of detoxification and excretion of the flavonoids 
themselves, let alone their generally poor bioavailability [66-68]. More investigation on these 
topics should be done in the future to fully clarify their risk to humans. 
3.4 Docking simulations 
In order to gain deeper insight into the inhibition of UGT1A1 by acacetin and kaempferol 
from the point of view of ligand-enzyme interactions, molecular docking simulations were 
performed, using a homology model of the human UGT1A1. A knowledge-based 
comparative modeling method (SYBYL Advanced Protein Modeling Package) was used to 
construct a 3D structure of UGT1A1. As shown in Figure 5, acacetin and kaempferol, as well 
as the two probe substrates of UGT1A1 (NCHN and NHPN), could be well-docked into the 
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catalytic domain of the enzyme, but the top scoring binding conformations of these 4 ligands 
differed considerably. The binding areas of NHPN, kaempferol and acacetin on UGT1A1 
highly overlapped, while the binding area of NCHN was clearly separated and distinguished 
(Figure 5). Furthermore, docking simulations demonstrated that kaempferol could form 
strong interactions with UDPGA, Ser375 and His376 via hydrogen-bonding (Figure S8), 
while acacetin could form strong interactions with UDPGA, Ser375 and Glu289 (instead of 
His376) via hydrogen-bonding (Figure S9). These findings are consistent with the 
experimental results, in which acacetin and kaempferol were both potent and non-competitive 
inhibitors toward UGT1A1-mediated NCHN-O-glucuronidation but functioned as 
competitive inhibitors toward UGT1A1-mediated NHPN-O-glucuronidation. 
 
4. Conclusion 
In summary, the inhibitory effects of flavonoids on UGT1A1, one of the most important 
human conjugative enzymes, have been systematically investigated. The results suggest that 
hydroxyl groups at the C-3 and C-7 positions of the flavones can enhance UGT1A1 inhibition, 
while flavonoids that carry glycoside groups displayed weak inhibition than corresponding 
aglycones. Detailed structure-inhibition relationships of flavonoids towards UGT1A1 have 
been summarized for the first time. Further investigation and inhibition kinetic analyses for 
acacetin and kaempferol, demonstrated that these two flavonoids are non-competitive 
UGT1A1 inhibitors toward UGT1A1-mediated NCHN-O-glucuronidation, but are 
competitive inhibitors toward UGT1A1-mediated NHPN-O-glucuronidation. The new 
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findings not only shed light on the structure of the UGT1A1 substrate binding site, but 
contribute valuable knowledge on the interactions between flavonoids and UGT1A1. All the 
information and knowledge that are presented here will be useful for avoiding potential 
food/herb-drug/endobiotic interactions in the clinic, as well as for the development of new 
flavonoid-type drugs without UGT1A1 inhibition.  
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Figure 1 The inhibitory effects of all tested the flavonoids (final concentration, 100 µM) on 
UGT1A1-mediated NCHN-O-glucuronidation in HLM. The data are presented as the means 
of triplicate determinations. 
Figure 2 The structure-inhibition relationship of flavonoids against UGT1A1-mediated 
NCHN-O-glucuronidation 
Figure 3 Inhibition type analysis of acacetin against UGT1A1 in HLM. Acacetin exerted a 
dose-dependent inhibition towards UGT1A1-catalyzed NCHN glucuronidation and NHPN 
glucuronidation reactions (A and B, respectively). Lineweaver-Burk plots of acacetin against 
UGT1A1-mediated NCHN-O-glucuronidation and NHPN-O-glucuronidation, both in HLM 
(C and D, respectively). Each point represents the mean of triplicate determinations. 
Figure 4 Inhibition type analysis of kaempferol against UGT1A1 in HLM. Kaempferol 
exerted a dose-dependent inhibition towards UGT1A1-catalyzed NCHN glucuronidation and 
NHPN glucuronidation reactions (A and B, respectively). Lineweaver-Burk plots of 
kaempferol against UGT1A1-mediated NCHN-O-glucuronidation and 
NHPN-O-glucuronidation in HLM (C and D, respectively). Each point represents the mean of 
triplicate determinations. 
Figure 5 The binding poses of NPHN, NCHN, kaempferol and acacetin in the active pocket 
of UGT1A1. (A) An overview of UGT1A1 binding site with kaempferol. (B) A closer and 
more detailed view of kaempferol bound at the active pocket of UGT1A1. (C) An overview 
of UGT1A1 binding with acacetin. (D) A closer and more detailed view of acacetin bound at 
the active pocket of UGT1A1. The four molecules are depicted in white, cyan, yellow and 
magenta, respectively. NPHN, NCHN were used to represent ligand-binding site I and ligand 
binding site II. UDPGA is shown in balls and sticks type. 
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Table 1. The IC50 value of the flavones towards human UGT1A1 using NCHN as the fluorescent probe substrate 
No. Compound R1 R2 R3 R4 R5 R6 R7 R8 R9       IC50 
(μM) 
1 3-Hydroxyflavone OH H H H H H H H H 16.393.83 
2 3-Methoxyflavone OCH3 H H H H H H H H >100 
3 3,6-Dihydroxyflavone OH H OH H H H H H H 23.83±2.44 
4 5-Hydroxyflavone H OH H H H H H H H >100 
5 5,6-Dihydroxyflavone H OH OH H H H H H H 16.291.46 
6 5-hydroxy-6-methoxyflavone H OH OCH3 H H H H H H 11.531.84 
ACCEPTED MANUSCRIPT
AC
CE
PTE
D M
AN
US
CR
IPT
 
28 
7 5,7-Dihydroxyflavone H OH H OH H H H H H 9.401.10 
8 5,6,7-Trimethoxyflavone H OCH3 OCH3 OCH3 H H H H H 9.86±1.01 
9 6-Hydroxyflavone H H OH H H H H H H 17.290.98 
10 6-Methoxyflavone H H OCH3 H H H H H H Activator 
11 6,7-Dimethoxybaicalein H OH OCH3 OCH3 H H H H H 5.390.96 
12 6,7-Dihydroxyflavone H H OH OH H H H H H 23.20±1.99 
13 7-Hydroxyflavone H H H OH H H H H H 9.232.09 
14 7,8-Dihydroxyflavone H H H OH OH H H H H 30.892.97 
15 7,4'-Dihydroxyflavone H H H OH H H H OH H 3.650.30 
16 7-hydroxy-4'-methoxyflavone H H H OH H H H OCH3 H >100 
17 3',4'-Dihydroxyflavone H H H H H H OH OH H 16.471.55 
18 Baicalein H OH OH OH H H H H H 12.430.69 
19 Baicalin H OH OH O-GluA H H H H H 39.293.67 
20 Scutellarein H OH OH OH H H H OH H 32.233.99 
21 Scutellarin H OH OH O-GluA H H H OH H 74.629.62 
22 Wogonin H OH H OH OCH3 H H H H 10.011.65 
23 Wogonoside H OH H O-GluA OCH3 H H H H >100 
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24 Luteolin H OH H OH H H OH OH H 7.780.57 
25 Orientin H OH H OH C-Glu H OH OH H 48.26±5.90 
26 Cynaroside H OH H O-Glu H H OH OH H 37.221.42 
27 Oroxylin A H OH OCH3 OH H H H H H 9.141.54 
28 Oroxyloside H OH OCH3 O-GluA H H H H H >100 
29 Apigenin H OH H OH H H H OH H 18.572.94 
30 Apigenin-7-O-glucronide H OH H O-GluA H H H OH H 25.10±4.52 
31 Apigenin 7-O-methyl ether H OH H OCH3 H H H OH H 4.79±0.75 
32 Hispidulin H OH OCH3 OH H H H OH H 6.230.90 
33 7-methoxybaicalein H OH OH OCH3 H H H H H 11.081.97 
34 8-Nitrobaicalein H OH OH OH NO2 H H H H 7.500.71 
35 Norwogonin H OH H OH OH H H H H 51.329.99 
36 Diosmetin H OH H OH H H OH OCH3 H 17.702.81 
37 Acacetin H OH H OH H H H OCH3 H 3.570.37 
38 Isovitexin H OH C-Glu OH H H H OH H 60.90±7.42 
39 Vitexin H OH H OH C-Glu H H OH H 61.70±8.82 
40 Eupatilin H OH OCH3 OH H H OCH3 OCH3 H 12.612.01 
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41 8-((dimethylamino)-methyl)-baicalein H OH OH OH R’ H H H H 69.20±10.64 
42 8-((dimethylamino)-methyl)-7-hydroxyflavonoid H H H OH R’ H H H H >100 
43 Flavopiridol H OH H OH R’’ Cl H H H >100 
44 Lysionotin H OH OCH3 OH OCH3 H H OCH3 H 9.181.25 
45 Galangin OH OH H OH H H H H H 5.030.29 
46 Quercetin OH OH H OH H H OH OH H 7.471.20 
47 Quercitrin O-Glu OH H OH H H OH OH H 12.39±1.25 
48 Morin OH OH H OH H OH H OH H 4.190.29 
49 Herbacetin OH OH H OH OH H H OH H 56.139.14 
50 Kaempferol OH OH H OH H H H OH H 3.340.40 
51 8-Methoxykaempferol OH OH H OH OCH3 H H OH H 6.560.56 
52 Myricetin OH OH H OH H H OH OH OH 10.461.55 
53 Anhydroicaritin OH OH H OH prenyl H H OCH3 H 3.93±0.49 
54 Icariside I OH OH H O-Glu prenyl H H OCH3 H 6.01±1.11 
55 Isorhamnetin OH OH H OH OH H OCH3 OH H 6.67±0.39 
56 Fisetin OH H H OH H H OCH3 OH H 11.49±1.92 
57 Protopanaxatriol (PPT) positive control 6.540.87 
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* GluA: Glucuronic acid; Glu: Glucose; rha: rhamnoside; R’ = CH2N(CH3)2; R’’ = CH(CH2CH2)(CHOHCH2)NCH3 
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Table 2. Inhibition kinetic parameters of acacetin and kaempferol against UGT1A1-mediated NCHN- or NHPN-O-Glucuronidation in HLM 
Inhibitor Substrate IC50 (μM) Ki (μM) The type of inhibition αKi (μM) 
Goodness of fit 
(R
2
) 
Acacetin 
NCHN 3.570.37 8.56±0.87 mixed 32.57±1.43 0.99 
NHPN 2.08±0.27 5.95±0.16 competitive n/a 0.99 
Kaempferol 
NCHN 3.34±0.18 1.74±0.29 noncompetitive n/a 0.97 
NHPN 2.33±0.33 0.68±0.24 competitive n/a 0.97 
* n/a: not applicable 
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Highlights 
1. 56 natural and synthetic flavonoids were collected and their inhibitory effects 
on UGT1A1 were assayed. 
2. The structure-activity relationships of flavonoids as UGT1A1 inhibitors were 
summarized. 
3. The inhibition mechanism of acacetin and kaempferol toward two different 
activities of UGT1A1 were carefully investigated. 
4. Docking simulations were conducted to explore the interactions between 
UGT1A1 and acacetin/kaempferol. 
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